Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Bullish +55

Atlas Wealth LLC Buys New Position in Eli Lilly and Company $LLY

AI-generated analysis

πŸ“ˆ Atlas Wealth LLC acquired a new position in Eli Lilly valued at approximately $1.225 million during the first quarter.

πŸ“Š Brighton Jones LLC increased its stake by 22% in the fourth quarter, now holding shares worth $7.409 million.

πŸ“‰ Revolve Wealth Partners raised its holdings by 2.8% in the fourth quarter, adding 40 shares to its portfolio.

πŸ“ˆ Schnieders Capital Management lifted its stake by 16.7% in the second quarter, purchasing an additional 1,141 shares.

πŸ’° Flow Traders U.S. LLC and Nebula Research & Development LLC established new stakes valued at $356,000 and $749,000 respectively.

πŸ“Š LLY stock opened at $1,178.01 with a market capitalization of $1.11 trillion and a P/E ratio of 41.85.

πŸ’΅ The company announced a quarterly dividend of $1.73 per share payable on September 10th to shareholders of record on August 14th.

πŸ“ˆ Barclays raised its price target from $1,350 to $1,400 and maintained an overweight rating in a recent report.

πŸ“‰ Wall Street Zen downgraded the stock from a strong-buy rating to a buy rating in a research report.

πŸ“Š Guggenheim boosted its target price to $1,273 and reaffirmed a buy rating in a July 13th note.

πŸ“ˆ Truist Financial raised its price target to $1,370 with a buy rating following a July 8th analysis.

πŸ“Š Sanford C. Bernstein increased its target price to $1,385 and assigned an outperform rating recently.

πŸ“‰ The consensus analyst rating is Moderate Buy with an average price target of $1,283.64 based on MarketBeat data.

Bullish Signals
  • Atlas Wealth LLC initiated a new position in Eli Lilly valued at approximately $1.225 million during the first quarter.
  • Brighton Jones LLC significantly increased its stake by 22% in the fourth quarter, demonstrating strong institutional confidence.
  • Schnieders Capital Management raised its holdings by 16.7% in the second quarter, adding over $6 million to its position.
  • Barclays upgraded its price target from $1,350 to $1,400 and maintained an overweight rating on the stock.
  • Guggenheim increased its price target to $1,273 while reaffirming a buy rating in a recent research note.
  • Truist Financial raised its price target to $1,370 and assigned a buy rating following a July 8th analysis.
  • Sanford C. Bernstein boosted its target price to $1,385 with an outperform rating in a Tuesday report.
  • The company maintains a strong balance sheet with a quick ratio of 1.10 and a current ratio of 1.50.
Risk Factors
  • Wall Street Zen downgraded the stock from a strong-buy rating to a buy rating, indicating some caution among analysts.
  • One analyst has assigned a sell rating to the stock, contributing to a consensus Moderate Buy rather than Strong Buy.
  • The average analyst price target of $1,283.64 is slightly below the recent opening price of $1,178.01, suggesting mixed near-term expectations.
Full Analysis
Institutional investor Atlas Wealth LLC purchased a new stake of approximately $1.225 million in Eli Lilly and Company (LLY) during the first quarter, adding 1,332 shares to its portfolio. Other notable institutional holders recently adjusted their positions, with Brighton Jones LLC increasing its stake by 22% in the fourth quarter and Revolve Wealth Partners raising holdings by 2.8%. Additionally, Schnieders Capital Management lifted its position by 16.7% in the second quarter, while Flow Traders U.S. LLC and Nebula Research & Development LLC established new stakes valued at roughly $356,000 and $749,000 respectively. The article details current market metrics for LLY, noting a stock price opening at $1,178.01 with a market capitalization of $1.11 trillion. Key financial ratios include a P/E ratio of 41.85 and a price-to-earnings-growth ratio of 1.47. The company maintains a beta of 0.51, with a quick ratio of 1.10 and a current ratio of 1.50. LLY recently announced a quarterly dividend of $1.73 per share payable on September 10th to shareholders of record on August 14th, representing an annualized yield of 0.6%. Wall Street analysts have issued mixed but generally positive ratings for the stock following recent reports. Barclays raised its price target from $1,350 to $1,400 with an overweight rating, while Guggenheim and Truist Financial increased their targets to $1,273 and $1,370 respectively, both maintaining buy ratings. Sanford C. Bernstein also upgraded its target to $1,385 with an outperform rating. The consensus rating remains Moderate Buy with an average price target of $1,283.64.